Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kirsten rat sarcoma viral oncogene homolog G13D mutation (KRAS G13D)
- Target
- KRAS G13D
- Molecular classification
- GTPase, Oncoprotein, Signal Transduction Protein
01
Overview
The KRAS G13D mutation is a missense mutation at codon 13 of the KRAS gene, where glycine (G) is replaced by aspartic acid (D). This alteration leads to constitutive activation of the KRAS protein, impacting cell signaling pathways involved in proliferation, differentiation, and survival. Tumors with the G13D mutation may exhibit intermediate sensitivity/resistance profiles when treated with anti-EGFR monoclonal antibodies. Direct therapeutic targeting remains challenging.
- Other names
- KRAS G13DKRAS p.G13DKRAS Gly13AspKRAS c.38G>AG13D KRAS
02
Mechanism of action
Inhibition of downstream effectors (e.g., MEK) or targeting parallel pathways in combination with EGFR blockade.
03
Biological functions
Signal transductionCell proliferationCell differentiationCell survivalRegulation of MAPK/ERK pathwayRegulation of PI3K/AKT pathway
04
Disease associations
CancerColorectal cancerNon-small cell lung cancer
05
Safety considerations
Resistance to EGFR inhibitorsOff-target effects of MEK inhibitorsDifficulty in directly targeting KRAS due to high-affinity nucleotide binding
06
Interacting drugs
Cetuximab
2 more in the full profile.
07
Biomarkers
KRAS G13D mutation statusEGFR expression
Beyond the preview
Go deeper on Kirsten rat sarcoma viral oncogene homolog G13D mutation (KRAS G13D).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kirsten rat sarcoma viral oncogene homolog G13D mutation (KRAS G13D).